16209 AML Risk Stratification: Influence of emerging cytogenetics and molecular markers on treatment decisions 4-5pm (CDT) - September 29, 2016
Emerging molecular genetic and cytogenetic alterations are changing the landscape of treatment decision-making in AML. Using an interactive, case study-based format, speakers will discuss the prognostic importance of cytogenetic and molecular marker testing and how results are used to develop risk-adapted treatment choices to achieve optimal outcomes for patients. Speakers will also discuss recommended standards of care for patients with intermediate- and high-risk AML.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.
If you have any questions regarding this activity, contact Nicole Heino, continuing education manager, Education and Training, NMDP/Be The Match at (800) 526-7809 ext. 4811, or email email@example.com.
At the conclusion of this activity, I will be able to:
- Describe which cytogenetic and molecular marker testing should be completed for patients newly diagnosed with AML
- Cite the latest research that revises categorization for intermediate- or high-risk disease
- Apply cytogenetic and molecular marker risk stratification to inform prognosis and guide therapeutic options
|Sergio Giralt, MD||Celgene, Sanofi, Jazz, Takeda, Amgen||Research, Advisory Board|
|Laura Michaelis, MD||Incyte, Celgene, Pfizer||Consultant, Stock Owner|
|Navneet Majhail, MD||Anthem Inc., Sanofi||Consultant, Speaker|
|Jackie Foster, MPH, RN||Pfizer||Stock Owner|
|Aaron Gerds, MD||Incyte, CTI Biopharma||Advisory Board|
|Jessica Altman, MD||Syros, BMS, Astellas, Janssen, ASH, NCCN||Advisory Board|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.